Optimal summary of information in longitudinal CA125 measurements for efficient ovarian cancer screening

被引:0
|
作者
Skates, SJ [1 ]
机构
[1] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
来源
JOURNAL OF CLINICAL LIGAND ASSAY | 2000年 / 23卷 / 02期
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Ovarian cancer mortality rates have changed little over 30 years despite therapeutic advances. Given the large proportion of cases discovered in late stages and consequent poor prognosis, and the excellent prognosis if discovered in early stages, screening is an appealing approach to investigate reducing ovarian cancer mortality, Due to the large scale of screening programs end the low incidence of ovarian cancer, it is paramount that the screening strategy is as efficient as possible. CA125 is a marker for ovarian cancer that shows promise in detecting most ovarian cancers preclinically. However, its efficiency could be substantially improved if longitudinal CA125 values were taken into account in the screening program, We provide a detailed description, with minimal mathematical notation, of a systematic statistical calculation to optimally summarize the information in longitudinal CA125 values. Based on this calculation we describe a strategy, called the risk of ovarian cancer algorithm (ROCA), which implements an efficient approach to screening for ovarian cancer based on longitudinal CA125 measurements.
引用
收藏
页码:150 / 154
页数:5
相关论文
共 50 条
  • [31] Beyond CA125: the coming of age of ovarian cancer biomarkers
    Sasaroli, Dimitra
    Coukos, George
    Scholler, Nathalie
    BIOMARKERS IN MEDICINE, 2009, 3 (03) : 275 - 288
  • [32] Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer
    Schorge, JO
    Drake, RD
    Lee, H
    Skates, SJ
    Rajanbabu, R
    Miller, DS
    Kim, JH
    Cramer, DW
    Berkowitz, RS
    Mok, SC
    CLINICAL CANCER RESEARCH, 2004, 10 (10) : 3474 - 3478
  • [33] Targeting CA125 transcription for ovarian cancer treatment.
    Yue, Er
    Yang, Guangchao
    Yao, Yuanfei
    Wang, Guangyu
    Zhang, Yanqiao
    Wang, Edward W.
    CANCER RESEARCH, 2021, 81 (13)
  • [34] CA125 based diagnosis and therapy in recurrent ovarian cancer
    Meier, W
    Baumgartner, L
    Stieber, P
    Hasholzner, U
    FatehMoghadam, A
    ANTICANCER RESEARCH, 1997, 17 (4B) : 3019 - 3020
  • [35] Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
    Weiland, Florian
    Martin, Karina
    Oehler, Martin K.
    Hoffmann, Peter
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (08) : 10568 - 10582
  • [36] Serum CA125 level before the development of ovarian cancer
    Kobayashi, H.
    Ooi, H.
    Yamada, Y.
    Sakata, M.
    Kawaguchi, R.
    Kanayama, S.
    Sumimoto, K.
    Terao, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2007, 99 (02) : 95 - 99
  • [37] SERUM CA125 LEVEL BEFORE THE DEVELOPMENT OF OVARIAN CANCER
    Kobayashi, H.
    Ooi, H.
    Yamada, Y.
    Sakata, M.
    Kawaguchi, R.
    Kanayama, S.
    Sumimoto, K.
    Terao, T.
    GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2008, 30 (03): : 91 - 96
  • [38] Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer
    Zhang, Minghai
    Cheng, Shanshan
    Jin, Yue
    Zhao, Yaqian
    Wang, Yu
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1875 (02):
  • [39] Monitoring Ovarian Cancer: CA125 Trial Stirs Controversy
    Chitale, Radha
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (18) : 1233 - 1233
  • [40] CANCER ASSOCIATED ANTIGENS CA15.3 AND CA125 OVARIAN-CANCER
    LOTZNIKER, M
    BABILONTI, L
    SCARABELLI, M
    ACQUISTAPACE, L
    MORATTI, R
    PAVESI, F
    CLINICAL CHEMISTRY, 1990, 36 (06) : 1051 - 1051